Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 5,818 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EXTEND Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

A Formative Evaluation For Improving Breast Cancer Hormone Receptor Testing in Tanzania

NCT05438511
View directory record Official record
Conditions
Breast Cancer
Interventions
Focus group, Organizational Readiness for Implementing Change
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 18, 2026, 2:42 AM EDT
Not listed Phase 1Phase 2 Interventional

Transcranial Electromagnetic Treatment (TEMT) Against Alzheimer's Disease

NCT04271163
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MemorEM
Device
Lead sponsor
NeuroEM Therapeutics, Inc.
Industry
Eligibility
63 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Not applicable Interventional

Intensive Intervention for Smokers - 6

NCT00217984
View directory record Official record
Conditions
Tobacco Use Disorder, Alcohol Dependence
Interventions
Usual Care, Extended cognitive behavior therapy
Other · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

Study of COV795 in Subjects With Osteoarthritis or Chronic Low Back Pain

NCT01451385
View directory record Official record
Conditions
Osteoarthritis, Low Back Pain
Interventions
COV795
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
42
States / cities
Tucson, Arizona • Anaheim, California • Buena Park, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2020 · Synced Oct 18, 2026, 2:42 AM EDT
Terminated Phase 3 Interventional

Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus

NCT00865592
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Type 2 Diabetes
Interventions
dutogliptin
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 85 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
Norwalk, California • Orange, California • Santa Ana, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2010 · Synced Oct 18, 2026, 2:42 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

NCT03689244
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
Selexipag, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 85 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
32
States / cities
La Jolla, California • Los Angeles, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 18, 2026, 2:42 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

NCT07506863
View directory record Official record
Conditions
Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia
Interventions
Mitapivat Matched Placebo, Mitapivat
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 18, 2026, 2:42 AM EDT
Enrolling by invitation Phase 3 Interventional

Clinical Trial of Vormatrigine in Adult Patients With Epilepsy

NCT07287163
View directory record Official record
Conditions
Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
Interventions
vormatrogine
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years to 85 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Miami, Florida • Miami Lakes, Florida • Naples, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)

NCT02705755
View directory record Official record
Conditions
Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease, Hypotension, Orthostatic, Orthostatic Hypotension, Pure Autonomic Failure With Orthostatic Hypotension, Parkinson Disease With Orthostatic Hypotension
Interventions
TD-9855, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
40 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Long Beach, California • Farmington Hills, Michigan • Berlin, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Oct 18, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional

A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

NCT01709734
View directory record Official record
Conditions
Prostate Cancer
Interventions
galeterone
Drug
Lead sponsor
LTN PHARMACEUTICALS, INC.
Industry
Eligibility
18 Years and older · Male only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
21
States / cities
Los Angeles, California • San Bernardino, California • Boca Raton, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 18, 2026, 2:42 AM EDT
Active, not recruiting Phase 2 Interventional

Rehabilitation and Cortical Remodeling After Surgical Intervention for Spinal Cord Injury

NCT04041063
View directory record Official record
Conditions
Spinal Cord Injuries, Tetraplegia, Cervical Spinal Cord Injury
Interventions
Upper limb robotic training, Nerve transfer surgery
Device · Procedure
Lead sponsor
Burke Medical Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 1 Interventional

Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels

NCT01867255
View directory record Official record
Conditions
Bariatric Surgery, Gastric Bypass, Roux-en-Y Gastric Bypass
Interventions
venlafaxine ER (extended-release) 75 mg
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert

NCT04061044
View directory record Official record
Conditions
Open Angle Glaucoma and Ocular Hypertension
Interventions
Ophthalmic Insert
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Not applicable Interventional

Comparative Effectiveness Trial of Two Reminder/Recall Methods to Increase Immunization Rates in Young Children

NCT01557621
View directory record Official record
Conditions
Immunization Rates
Interventions
Collaborative Pop-Based R/R: Phone/Mail Group, Collaborative Pop-Based R/R: Mail-Only Group, Practice-based Recall
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Months to 5 Years
Enrollment
68,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Results available

An Analysis of the Efficacy of a Pre-Emptive Multimodal Pain Regimen in Reducing Acute Post-Operative Pain and Narcotic Pain Medication Requirements in Spine Surgery

NCT04522206
View directory record Official record
Conditions
Pain, Postoperative, Spine Injuries and Disorders, Narcotic Use
Interventions
Pre-op Multimodal analgesia (MMA) regimen + standard post-op oxycodone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs

NCT01527006
View directory record Official record
Conditions
Central Nervous System
Interventions
perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years to 11 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
23
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Gulf Breeze, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Not applicable Interventional

Comparison of Immediate vs Gradual Switch to Divalproex in Adults With Intellectual Disability

NCT00347152
View directory record Official record
Conditions
Epilepsy
Interventions
Divalproex
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2008 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Results available

Interventions for Children With Attention and Reading Disorders

NCT01133847
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Reading Disabilities
Interventions
Methylphenidate, Intensive reading instruction, Parent Training, Mixed Salt Amphetamine, Atomoxetine, Guanfacine
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
7 Years to 12 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies

NCT00720798
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Disease-modifying anti-rheumatic drugs, Non-steroidal anti-inflammatory drugs, Oral corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,067 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
138
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 2 Interventional

Safety Study of JTT-302 in Subjects With Low HDL-C Levels

NCT00748852
View directory record Official record
Conditions
Dyslipidemia
Interventions
JTT-302
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 18, 2026, 2:42 AM EDT
Recruiting Phase 3 Interventional

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

NCT07671911
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
NAL ER, Placebo
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
22
States / cities
Newport Beach, California • Palm Springs, California • Redding, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 18, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional Results available

Propranolol in Treating Hypoglycemia Unawareness

NCT03161964
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Propranolol 80 Mg Oral Capsule, Extended Release, Placebo oral capsule
Drug
Lead sponsor
Anu Sharma
Other
Eligibility
21 Years to 59 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

NCT01470599
View directory record Official record
Conditions
Crohn's Disease
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 76 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
32
States / cities
Oceanside, California • Lafayette, Colorado • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 18, 2026, 2:42 AM EDT
Completed Not applicable Interventional

Timing of Active Void Trials After Urogynecologic Procedures

NCT05885958
View directory record Official record
Conditions
Postoperative Care, Urinary Catheters, Urogynecology
Interventions
Time
Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 18, 2026, 2:42 AM EDT